Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Currently, there are limited therapeutic options available for chronic hepatitis C (HCV) patients who fail treatment with peginterferon α (PEG IFN) + ribavirin (RBV). An option is retreatment with a second course PEG-IFN + RBV. However, the virologic clearance with this option is unknown. Thus, we evaluated the outcome of our cohort of patients with chronic HCV who achieved a sustained viral response when retreated with PEG IFN plus RBV after having no response to an initial course of PEG IFN plus RBV. Nonresponse to treatment was defined as failure to achieve an early virologic response by week 12 or presence of detectable HCV RNA at week 24 or after completion of PEG-IFN + RBV therapy. Twenty patients (12 [60%] men; 8 [40%] women) were treated with PEG IFN α-2b plus RBV and PEG IFN α-2a plus RBV. The mean age of the patients was 50 years, 85% were white, 95% had genotype 1, and 35% had cirrhosis. Prior to the first course of PEG IFN plus RBV, 12 (60%) of 20 patients had no prior treatment for Hepatitis C. After the second course of PEG IFN plus RBV, 2 (10%) of 20 patients achieved a sustained virologic response. These results suggest marginal benefit of retreatment of patients with chronic HCV with another course of PEG IFN plus RBV after they have not responded to an initial course of PEG IFN plus RBV.
- Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?
Digestive Diseases and Sciences
Volume 52, Issue 3 , pp 732-736
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- Hepatitis C
- Industry Sectors
- Author Affiliations
- 1. Transplant Medicine, Mayo Clinic, Scottsdale, Arizona, USA
- 2. Division of Gastroenterology and Hepatology, Transplant Medicine, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, Arizona, 85259, USA